Format

Send to

Choose Destination
Int J Antimicrob Agents. 2020 Mar 6:105933. doi: 10.1016/j.ijantimicag.2020.105933. [Epub ahead of print]

Arguments in favour of remdesivir for treating SARS-CoV-2 infections.

Author information

1
Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
2
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France; IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
3
Department of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
4
Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
5
Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.

KEYWORDS:

Betacoronavirus; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2; Wuhan pneumonia

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center